Insmed reported $-101.31M in EBIT for its fiscal quarter ending in June of 2026.





Ebit Change Date
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Cytokinetics USD -179.17M 2.05M Jun/2026
DBV Technologies USD -47.9M 2.85M Mar/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -101.31M 98.97M Jun/2026
Novartis USD 4.18B 118M Mar/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026